The CheckMate 649 trial demonstrated that the first-line treatment with nivolumab plus chemotherapy led to a statistically significant survival benefit compared to chemotherapy alone among gastric cancer patients with PD-L1 expression ≥5% (8). This evidence concerns the gene CD274 and gastric cancer.